Results 71 to 80 of about 31,178 (269)

Oncolytic Virus Engineering and Utilizations: Cancer Immunotherapy Perspective

open access: yesViruses, 2023
Oncolytic viruses have positively impacted cancer immunotherapy over the past 20 years. Both natural and genetically modified viruses have shown promising results in treating various cancers.
Palaniyandi Muthukutty, So Young Yoo
doaj   +1 more source

Immunotherapeutic potential of oncolytic vaccinia virus [PDF]

open access: yes, 2014
The concept of oncolytic viral therapy was based on the hypothesis that engineering tumor-selectivity into the replication potential of viruses would permit direct destruction of tumor cells as a result of viral-mediated lysis, resulting in amplification
Thorne, SH
core   +1 more source

Overview of the pre-clinical and clinical studies about the use of CAR-T cell therapy of cancer combined with oncolytic viruses

open access: yesWorld Journal of Surgical Oncology, 2022
Background Cancer is one of the critical issues of the global health system with a high mortality rate even with the available therapies, so using novel therapeutic approaches to reduce the mortality rate and increase the quality of life is sensed more ...
Ali Zarezadeh Mehrabadi   +6 more
doaj   +1 more source

Markedly enhanced intratumoral spread and antitumor effect of oncolytic adenovirus expressing decorin [PDF]

open access: yes, 2008
With the aim of improving viral distribution and tumor penetration, we have engineered decorin expressing replication-incompetent (dl-LacZ-DCNG) and -competent (Ad-[DELTA]E1B-DCNG) adenoviruses.
A-Rum Yoon   +7 more
core   +1 more source

A Multiple‐Model‐Informed Drug‐Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination With Pembrolizumab

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 572-582, March 2025.
ABSTRACT The antitumor efficacy of an intratumoral injection of a genetically engineered oncolytic vaccinia virus carrying human IL‐7 and murine IL‐12 genes (hIL‐7/mIL‐12‐VV) was demonstrated in CT26.WT‐bearing mice. In the CT26.WT‐bearing mouse model, the efficacy of the combination of hIL‐7/mIL‐12‐VV plus the anti‐programmed cell death protein (PD)‐1
Akihiro Yamada   +13 more
wiley   +1 more source

Engineered oncolytic virus coated with anti-PD-1 and alendronate for ameliorating intratumoral T cell hypofunction

open access: yesExperimental Hematology & Oncology
Background Glioblastoma is a highly aggressive and devastating primary brain tumor that is resistant to conventional therapies. Oncolytic viruses represent a promising therapeutic approach for glioblastoma by selectively lysing tumor cells and eliciting ...
Yufu Zhu   +9 more
doaj   +1 more source

Minimal hepatic toxicity of Onyx-015: spatial restriction of coxsackie-adenoviral receptor in normal liver. [PDF]

open access: yes, 2007
We administered an adenoviral vector, Onyx-015, into the hepatic artery of patients with metastatic colorectal cancer involving the liver. Thirty-five patients enrolled in this multi-institutional phase I/II trial received up to eight arterial infusions ...
Au, T   +5 more
core  

New Advances of Degradable Magnesium‐Based Metal Biomaterials in the Field of Orthopedics

open access: yesRare Metals, EarlyView.
ABSTRACT Based on their outstanding biomechanical properties and superior osteogenic activity, magnesium (Mg) and its alloys have been extensively investigated for their biocompatibility and therapeutic efficacy in treating fractures and bone defects.
Jia‐Nan Yu   +8 more
wiley   +1 more source

Designing herpes viruses as oncolytics

open access: yesMolecular Therapy - Oncolytics, 2015
Oncolytic herpes simplex virus (oHSV) was one of the first genetically-engineered oncolytic viruses. Because herpes simplex virus (HSV) is a natural human pathogen that can cause serious disease, it is incumbent that it be genetically-engineered or significantly attenuated for safety.
Peters, Cole, Rabkin, Samuel
openaire   +4 more sources

Oncolytic Herpes Simplex Viral Therapy: A Stride toward Selective Targeting of Cancer Cells

open access: yesFrontiers in Pharmacology, 2017
Oncolytic viral therapy, which makes use of replication-competent lytic viruses, has emerged as a promising modality to treat malignancies. It has shown meaningful outcomes in both solid tumor and hematologic malignancies.
Dhaval S. Sanchala   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy